|
 Uzbekistan is rapidly consolidating its position as one of the most promising pharmaceutical markets in Eurasia, combining strong economic growth, proactive state policy, and a clear strategic pivot toward high-value pharmaceutical manufacturing and biotechnology.
With a population of over 38 million and rising healthcare demand, the country offers a compelling growth story for global pharmaceutical companies seeking expansion into Central Asia and CIS markets.
A market defined by momentum
Uzbekistan’s pharmaceutical sector has entered a phase of sustained, high-speed expansion, with the total market now estimated at $3.1 billion and continuing to grow at one of the fastest rates in the region. Domestic manufacturing has exceeded $600 million, underscoring a rapid transition toward localization and a strengthening industrial base.
This growth is underpinned by:
- Increasing public and private healthcare expenditure.
- Expanding access to medicines.
- Strong demographic fundamentals.
Crucially, the market remains significantly underpenetrated, creating substantial room for future expansion and long-term investment.
Strong government backing and clear strategy
A defining feature of Uzbekistan’s pharmaceutical rise is the active role of the state in shaping the sector’s development.
At the centre of this transformation is the Pharmaceutical Industry Development Agency, which operates under the Ministry of Health and serves as a single-window platform for international investors and partners.
The government has implemented a comprehensive framework to accelerate industry growth, including:
- Tax holidays and customs exemptions for pharmaceutical investors
- Dedicated free economic zones for pharma manufacturing
- Streamlined regulatory procedures and digitalization initiatives
- Direct facilitation of foreign partnerships and joint ventures
This coordinated approach significantly reduces entry barriers and enhances investor confidence.
Bio Pharma City: A new centre of innovation
The cluster transformation of Tashkent Pharma Park into Bio Pharma City represents a major milestone in Uzbekistan’s transition toward innovation-driven pharmaceutical development.
The cluster is designed as a fully integrated ecosystem, combining advanced GMP-compliant manufacturing with research and biotechnology centers, clinical trial infrastructure, and education and workforce development facilities. Key components include a Genome and Biotechnology Research Center, Preclinical and Clinical Research Center, International Pharmaceutical Technical University, National R&D Institute, Pharmaceutical Safety Center (Regulatory authority), and a Vivarium - collectively forming a vertically integrated platform for pharmaceutical innovation and industrial scale-up.
Bio Pharma City is not only a national project - it is positioned as a regional platform for pharmaceutical production, R&D, and export, connecting investors to markets across Central Asia, the CIS, and beyond. In its current development phase, Bio Pharma City is placing a strategic emphasis on advancing biotechnology, prioritizing the localization of biopharmaceutical production, the development of biosimilars, and the expansion of capabilities in genetic engineering and cell-based research.
Rapid industrial growth and export expansion
Uzbekistan has made significant progress in strengthening its domestic pharmaceutical base:
- Production has increased more than threefold in recent years.
- Export reach now spans over 50 countries.
- A growing network of modern manufacturing facilities is emerging.
This industrial expansion reflects a broader strategic shift toward localization, value creation, and export-oriented production.
Attractive investment environment
Uzbekistan offers a unique combination of market opportunity and policy support, making it one of the most attractive pharmaceutical investment destinations in the region. This momentum is already translating into tangible results—within just two years, 32 investment projects have been launched within Bio Pharma City alone, underscoring strong investor confidence and rapid ecosystem development.
Key advantages:
- High-growth and underserved market.
- Strategic location bridging Europe and Asia.
- Competitive production and labour costs.
- Strong institutional support and facilitation.
High-potential segments
- Oncology and specialty medicines.
- Biopharmaceuticals and biosimilars.
- Contract manufacturing (CMO/CDMO).
- Nutraceuticals and preventive healthcare.
Foreign companies are increasingly leveraging Uzbekistan as a regional production base, with localization strategies enabling both domestic market access and export expansion.
Advancing toward global standard
Uzbekistan is actively modernizing its regulatory and quality infrastructure to align with international best practices, with a growing emphasis on integration into global pharmaceutical value chains.
Key areas of progress include:
- Strengthening GMP compliance frameworks.
- Developing advanced pharmacovigilance systems.
- Digitalizing regulatory processes.
- Expanding institutional capacity through international cooperation.
In parallel, the country has prioritized obtaining EU-GMP certifications for domestic manufacturers, with the government supporting this process by covering certification fees, aimed at accelerating compliance with European standards and enhancing export readiness.
These efforts are reinforcing Uzbekistan’s position as a reliable, quality-assured pharmaceutical producer with increasing credibility in international markets.
A strategic gateway to Eurasia
Uzbekistan’s geographic position gives it a distinct competitive advantage. As the largest market in Central Asia, it serves as a natural gateway to neighbouring countries, including fast-growing and underserved markets, while also providing strategic access to the broader CIS market.
Combined with improving logistics and trade integration, this positions Uzbekistan as a regional hub for distribution and manufacturing, enabling companies to efficiently reach both Central Asian and CIS consumers from a single production base.
Outlook: From growth to leadership
Uzbekistan’s pharmaceutical sector is moving beyond rapid growth toward structural transformation and global integration.
With continued investment, policy consistency, and technological upgrading, the country is well positioned to become:
- A leading pharmaceutical manufacturing hub in Central Asia.
- A platform for export-oriented production.
- An emerging centre for biotechnology and innovation.
Conclusion
Uzbekistan is no longer simply a developing pharmaceutical market - it is becoming a strategic destination for global pharma investment.
The convergence of strong government support, expanding industrial capacity, and a forward-looking innovation agenda creates a powerful foundation for long-term growth.
For international pharmaceutical companies, Uzbekistan represents not just a market - but a gateway to Eurasia’s next phase of healthcare and life sciences development.
(Author is chief international relations and public relations specialist, Pharmaceutical Industry Development Agency, Ministry of Health, Republic of Uzbekistan)
|